5,585 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Purchased by JustInvest LLC

JustInvest LLC bought a new position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,585 shares of the life sciences company’s stock, valued at approximately $382,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IART. Amundi Pioneer Asset Management Inc. purchased a new position in Integra LifeSciences during the first quarter worth about $329,000. Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Integra LifeSciences by 2.9% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 24,352 shares of the life sciences company’s stock worth $1,662,000 after purchasing an additional 695 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Integra LifeSciences by 1.4% in the 2nd quarter. Principal Financial Group Inc. now owns 247,120 shares of the life sciences company’s stock worth $16,863,000 after purchasing an additional 3,414 shares during the period. Group One Trading L.P. purchased a new position in shares of Integra LifeSciences in the 2nd quarter worth about $134,000. Finally, Susquehanna Fundamental Investments LLC raised its holdings in shares of Integra LifeSciences by 3.6% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 41,619 shares of the life sciences company’s stock worth $2,840,000 after purchasing an additional 1,450 shares during the period. Hedge funds and other institutional investors own 90.19% of the company’s stock.

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 3,450 shares of the firm’s stock in a transaction that occurred on Friday, November 5th. The stock was sold at an average price of $71.59, for a total transaction of $246,985.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tru St Partnership, L.P. sold 75,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 18th. The shares were sold at an average price of $68.59, for a total value of $5,144,250.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 282,725 shares of company stock valued at $19,669,586. Insiders own 4.20% of the company’s stock.

IART stock opened at $68.79 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 3.32. Integra LifeSciences Holdings Co. has a 1 year low of $61.85 and a 1 year high of $77.40. The firm has a market cap of $5.83 billion, a P/E ratio of 27.08, a price-to-earnings-growth ratio of 1.50 and a beta of 1.20. The stock has a 50-day simple moving average of $66.95 and a 200-day simple moving average of $69.06.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 1st. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. Integra LifeSciences had a return on equity of 17.33% and a net margin of 14.19%. The business had revenue of $386.86 million during the quarter, compared to analyst estimates of $384.47 million. During the same quarter last year, the firm earned $0.80 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. On average, equities research analysts predict that Integra LifeSciences Holdings Co. will post 3.15 EPS for the current year.

A number of equities analysts have recently commented on IART shares. JMP Securities restated a “buy” rating on shares of Integra LifeSciences in a report on Wednesday, November 3rd. JPMorgan Chase & Co. upgraded Integra LifeSciences from an “underweight” rating to a “neutral” rating and set a $75.00 price objective on the stock in a report on Friday, December 17th. Finally, Credit Suisse Group raised their price objective on Integra LifeSciences from $84.00 to $87.00 and gave the stock an “outperform” rating in a report on Wednesday, November 3rd. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $77.22.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

Featured Article: Overweight

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.